BRPI0415620A - uso de cátions metálicos para melhorar a atividade funcional de anticorpos - Google Patents

uso de cátions metálicos para melhorar a atividade funcional de anticorpos

Info

Publication number
BRPI0415620A
BRPI0415620A BRPI0415620-0A BRPI0415620A BRPI0415620A BR PI0415620 A BRPI0415620 A BR PI0415620A BR PI0415620 A BRPI0415620 A BR PI0415620A BR PI0415620 A BRPI0415620 A BR PI0415620A
Authority
BR
Brazil
Prior art keywords
metal cations
functional activity
improve antibody
antibody functional
improve
Prior art date
Application number
BRPI0415620-0A
Other languages
English (en)
Inventor
Dominique Bourel
Arnaud Glacet
Sylvie Jorieux
Enrico Stura
Frederic Ducancel
Jean-Luc Teillaud
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BRPI0415620A publication Critical patent/BRPI0415620A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE CáTIONS METáLICOS PARA MELHORAR A ATIVIDADE FUNCIONAL DE ANTICORPOS". A presente invenção refere-se ao uso de cátions metálicos, em particular zinco, para melhorar a atividade funcional de anticorpos. Mais particularmente, a referida invenção é concernida com composições farmacêuticas, compreendendo anticorpos com cátions metálicos.
BRPI0415620-0A 2003-10-20 2004-10-20 uso de cátions metálicos para melhorar a atividade funcional de anticorpos BRPI0415620A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312228A FR2861079B1 (fr) 2003-10-20 2003-10-20 Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps.
PCT/FR2004/002687 WO2005040216A2 (fr) 2003-10-20 2004-10-20 Utilisation de cations metalliques pour cristalliser le fragment fc d’un anticorps rhesus d

Publications (1)

Publication Number Publication Date
BRPI0415620A true BRPI0415620A (pt) 2006-12-12

Family

ID=34385293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415620-0A BRPI0415620A (pt) 2003-10-20 2004-10-20 uso de cátions metálicos para melhorar a atividade funcional de anticorpos

Country Status (8)

Country Link
EP (1) EP1689785A2 (pt)
JP (1) JP2007537990A (pt)
AU (1) AU2004283925A1 (pt)
BR (1) BRPI0415620A (pt)
CA (1) CA2542928A1 (pt)
FR (1) FR2861079B1 (pt)
IL (1) IL175026A0 (pt)
WO (1) WO2005040216A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894982A1 (fr) * 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
EP2787006B1 (en) * 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 antibody which binding is Ca2+ dependent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE911547A1 (en) * 1990-05-08 1991-11-20 Scripps Clinic Res Metal binding proteins
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2894982A1 (fr) * 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs

Also Published As

Publication number Publication date
AU2004283925A1 (en) 2005-05-06
JP2007537990A (ja) 2007-12-27
CA2542928A1 (fr) 2005-05-06
FR2861079A1 (fr) 2005-04-22
IL175026A0 (en) 2006-08-20
WO2005040216A3 (fr) 2005-10-20
FR2861079B1 (fr) 2007-09-28
EP1689785A2 (fr) 2006-08-16
WO2005040216A2 (fr) 2005-05-06

Similar Documents

Publication Publication Date Title
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
BRPI0513738A (pt) sensor transdutor acústico eletromagnético flexìvel
BR0211039A (pt) Composição condicionadora para os cabelos e uso de uma composição condicionadora para os mesmos
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
RS52843B (en) THE NEW IS THE HYDROGEN SULPHATE
EP1704853A3 (en) Water-in-silicone emulsion compositions
TW200724159A (en) Stable emulsion composition
BR0300119A (pt) Composição aquosa, e, estrutura compósita
HRP20050611A2 (en) Combination medicament
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
BRPI0415620A (pt) uso de cátions metálicos para melhorar a atividade funcional de anticorpos
NZ528138A (en) Stud assembly with plate between studs having longitudinal U or V shape for sound attenuation
BRPI0510903A (pt) composição cosmética de spray, composição cosmética de spray desodorante, produto e método de tratamento cosmético
WO2004075028A3 (en) Systems and methods for variable rebate and incentive programs
BRPI0406466A (pt) Composição oral e uso de perlita
Martin Study of time as being according to the Keraakie people of Southwest Papua New Guinea
Mohr Neopaganismus
BR0105964A (pt) Pulseira elástica
HN2002000092A (es) Nuevas arilsufonamidas como agentes antivirales.
TH30962S1 (th) หน้าตัดโลหะ
GT200400212A (es) Agentes para la reduccion de peso
TH94166S (th) อุปกรณ์ชี้สำหรับคอมพิวเตอร์
TH28896S1 (th) อุปกรณ์ชี้สำหรับคอมพิวเตอร์

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LFB BIOTECHNOLOGIES (FR)

Free format text: TRANSFERIDO DE: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.